All AbMole products are for research use only, cannot be used for human consumption.
Erenumab is a first-in-class fully human monoclonal CGRP antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the research of episodic migraine.
| CAS Number | 1582205-90-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[1] Abhigyan Datta, et al. Pain Manag. Erenumab for episodic migraine
[3] No authors listed. Erenumab
[4] No authors listed. Erenumab
[5] Peter J Goadsby, et al. N Engl J Med. A Controlled Trial of Erenumab for Episodic Migraine
| Related CGRP Receptor Products |
|---|
| MK-3207 hydrochloride
MK-3207 hydrochloride is a potent CGRP receptor antagonist with IC50 of 0.12 nM. |
| Rimegepant
Rimegepant, also known as BMS-927711, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist with a Ki value of 0.027 nM. |
| BAR 501 impurity |
| MK-0974
MK-0974 (Telcagepant) is a highly potent, selective and orally bioavailable CGRP receptor antagonist with Ki values of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors respectively. |
| BAR501
BAR501 is a potent and selective agonist of GPBAR1 with an EC50 of 1 μM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
